Logo

Vox Markets

Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.

Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.

1 views
2 years ago
Author: Vox Markets

Money
Stocks
Investing
AIM
Stock Market
Shares
Equities
Stocks to Follow
Markets
Pharma
HVO
hVivo
Main Market
AIM Market
respiratory syncytial virus
Pharmaceutical
Powered bySeeen logo